|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTRNR2L1 |
Gene summary for MTRNR2L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTRNR2L1 | Gene ID | 100462977 |
| Gene name | MT-RNR2 like 1 | |
| Gene Alias | HN1 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | P0CJ68 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100462977 | MTRNR2L1 | SYSMH3 | Human | Oral cavity | OSCC | 1.77e-03 | -1.54e-01 | 0.2442 |
| 100462977 | MTRNR2L1 | SYSMH4 | Human | Oral cavity | OSCC | 1.77e-03 | -1.54e-01 | 0.1226 |
| 100462977 | MTRNR2L1 | SYSMH5 | Human | Oral cavity | OSCC | 3.73e-03 | -1.54e-01 | 0.0647 |
| 100462977 | MTRNR2L1 | GSM5252126_BPH283PrGF_Via | Human | Prostate | BPH | 1.16e-07 | -2.32e-01 | -0.1771 |
| 100462977 | MTRNR2L1 | GSM5252127_BPH283PrSF_Via | Human | Prostate | BPH | 7.99e-04 | -1.29e-02 | -0.1453 |
| 100462977 | MTRNR2L1 | GSM5252128_BPH327PrGF_Via | Human | Prostate | BPH | 3.07e-40 | 1.29e+00 | -0.1688 |
| 100462977 | MTRNR2L1 | GSM5252129_BPH327PrSF_Via | Human | Prostate | BPH | 4.29e-45 | 2.77e+00 | -0.1697 |
| 100462977 | MTRNR2L1 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 4.67e-29 | -8.45e-01 | -0.1972 |
| 100462977 | MTRNR2L1 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 1.56e-26 | -7.85e-01 | -0.2126 |
| 100462977 | MTRNR2L1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 7.51e-20 | 1.43e+00 | -0.2247 |
| 100462977 | MTRNR2L1 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 1.21e-52 | -1.11e+00 | -0.1433 |
| 100462977 | MTRNR2L1 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 2.22e-50 | -1.11e+00 | -0.1833 |
| 100462977 | MTRNR2L1 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.34e-53 | -1.11e+00 | -0.23 |
| 100462977 | MTRNR2L1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 6.36e-50 | -1.11e+00 | -0.23 |
| 100462977 | MTRNR2L1 | 047563_1562-all-cells | Human | Prostate | BPH | 1.07e-51 | -1.11e+00 | 0.0791 |
| 100462977 | MTRNR2L1 | 048752_1579-all-cells | Human | Prostate | BPH | 1.39e-50 | -1.11e+00 | 0.1008 |
| 100462977 | MTRNR2L1 | 052095_1628-all-cells | Human | Prostate | BPH | 1.43e-46 | -1.10e+00 | 0.1032 |
| 100462977 | MTRNR2L1 | 052097_1595-all-cells | Human | Prostate | BPH | 1.54e-47 | -1.11e+00 | 0.0972 |
| 100462977 | MTRNR2L1 | 052099_1652-all-cells | Human | Prostate | BPH | 5.24e-43 | -1.09e+00 | 0.1038 |
| 100462977 | MTRNR2L1 | Dong_P1 | Human | Prostate | Tumor | 3.01e-48 | -1.10e+00 | 0.035 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097194 | Liver | HCC | execution phase of apoptosis | 48/7958 | 85/18723 | 6.47e-03 | 2.63e-02 | 48 |
| GO:1900117 | Liver | HCC | regulation of execution phase of apoptosis | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |